Severe hypertriglyceridemia associated with calaspargase pegol
Calaspargase pegol is currently the only pegylated asparaginase product accessible to children, adolescents, and young adults aged 1 month to 21.5 years in the United States. Despite a growing recognition of its real-world toxicity profile, hypertriglyceridemia has not yet been described in depth with calaspargase pegol. Herein we describe our clinical observations of six patients who experienced significant hypertriglyceridemia following exposure to calaspargase pegol, warranting intensive care in several cases. Potential confounding risk factors and management strategies of this presumed toxicity are explored.
Authors
- Paul J. Galardy (ORCID: https://orcid.org/0000-0002-0322-8882)
- Siobhán T. Pittock (ORCID: https://orcid.org/0000-0002-2616-7349)
- Jessica Kalmes
- Madeleine O’Keefe
- Alexis Kuhn (ORCID: https://orcid.org/0000-0001-5256-5001)
- Mira A. Kohorst (ORCID: https://orcid.org/0000-0002-1865-7444)
- Mostafa Salama (ORCID: https://orcid.org/0009-0001-7451-1503)
- Catherine E. Martin (ORCID: https://orcid.org/0000-0003-2855-9503)
- Ashley A. Walter
- John Guggenberger
Institutions
- University of Minnesota Rochester (US)
- Mayo Clinic in Arizona (US)
- Minnesota Oncology (US)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1080/10428194.2025.2543578
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00